Wenqin Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenqin Zhang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jiaodi Cai
Department of Pathology, The Fourth Hospital of Changsha (Integrated Traditional Chinese and Western Medicine Hospital of Changsha, Changsha Hospital of Hunan Normal University), Hunan, China
2 shared publications - Jinwu Peng
Department of Pathology Xiangya Hospital Central South University Changsha China
2 shared publications - Yuanliang Yan
Department of Pharmacy, The Hunan Institute of Pharmacy Practice and Clinical Research, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Zhijie Xu
Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
2 shared publications - Abhimanyu Thakur
The Pritzker School of Molecular Engineering, the University of Chicago
1 shared publication Chuyi Tan
Sepsis Translational Medicine Key Lab of Hunan Province, Central South University, Changsha, Hunan, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Myxoid malignant solitary fibrous tumor in the retroperitoneum: A case report and literature review
Solitary fibrous tumor (SFT) is a spectrum of mesenchymal tumors characterized by a branching (staghorn-like) vascular pattern and the specific NAB2 :: STAT6 gene fusion. Myxoid SFT is a rare histological variant defined by myxoid stroma constituting over 50% of the tumor volume. Although most myxoid SFTs exhibit benign or indolent behavior, recent reports have demonstrated that this variant can also exhibit aggressive biological behavior. To our knowledge, malignant myxoid SFT arising in the retroperitoneum with integrative clinicopathological and molecular characterization has been rarely documented. We report a case of malignant myxoid SFT arising in the retroperitoneum and discuss its clinicopathological features with a literature review. A woman in her mid-50s presented with lower abdominal pain for over one month. Imaging revealed a pelvic mass that was initially clinically diagnosed as a uterine leiomyoma. Intraoperative exploration identified the mass in the retroperitoneum, and complete resection was performed. Gross examination showed a tumor measuring 11 cm in greatest dimension with a gray-white to gray-red, soft cut surface, predominantly gelatinous in appearance. Histopathological examination revealed a spindle cell tumor with prominent myxoid stroma (approximately 60% of the tumor volume), a mitotic count of approximately 10/10 high-power fields (HPF; equivalent to 5/mm 2 ), and coagulative tumor necrosis (approximately 15%). Immunohistochemistry demonstrated diffuse strong positivity for CD34 and STAT6, weak positivity for Bcl-2, and focal weak positivity for CDK4 and MDM2. DNA-based next-generation sequencing (NGS) detected an NAB2 :: STAT6 fusion gene and no MDM2 amplification, confirming the diagnosis of myxoid malignant SFT. According to the modified Demicco risk stratification model (age ≥55 years, tumor size 11 cm, mitotic count ≥4/10 HPF, necrosis ≥10%), the case scored 6 points, placing it in the high-risk category. The patient received adjuvant radiotherapy (45 Gy in 25 fractions to the PCTV) and remained disease-free without evidence of recurrence or metastasis throughout the 17-month follow-up period. Malignant myxoid SFT arising in the retroperitoneum is extremely rare and poses significant diagnostic challenges. Accurate diagnosis can be supported by histopathological and immunohistochemical examinations (including CD34, STAT6, and BCL2), and molecular detection of the NAB2 :: STAT6 fusion gene can serve as a valuable adjunct, especially in cases where morphological and immunohistochemical findings are atypical or when differential diagnosis is challenging. Complete surgical resection is the cornerstone of treatment. Adjuvant therapy and close long-term surveillance should be considered for patients with high-risk features. To the best of our knowledge, this case supplements the clinicopathological data of this rare entity occurring in the retroperitoneum with overt malignant biological behavior, and further case reports and studies are essential to refine the diagnostic criteria and optimize treatment strategies for this tumor.
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessMyxoid malignant solitary fibrous tumor in the retroperitoneum: A case report and literature review
Solitary fibrous tumor (SFT) is a spectrum of mesenchymal tumors characterized by a branching (staghorn-like) vascular pattern and the specific NAB2 :: STAT6 gene fusion. Myxoid SFT is a rare histological variant defined by myxoid stroma constituting over 50% of the tumor volume. Although most myxoid SFTs exhibit benign or indolent behavior, recent reports have demonstrated that this variant can also exhibit aggressive biological behavior. To our knowledge, malignant myxoid SFT arising in the retroperitoneum with integrative clinicopathological and molecular characterization has been rarely documented. We report a case of malignant myxoid SFT arising in the retroperitoneum and discuss its clinicopathological features with a literature review. A woman in her mid-50s presented with lower abdominal pain for over one month. Imaging revealed a pelvic mass that was initially clinically diagnosed as a uterine leiomyoma. Intraoperative exploration identified the mass in the retroperitoneum, and complete resection was performed. Gross examination showed a tumor measuring 11 cm in greatest dimension with a gray-white to gray-red, soft cut surface, predominantly gelatinous in appearance. Histopathological examination revealed a spindle cell tumor with prominent myxoid stroma (approximately 60% of the tumor volume), a mitotic count of approximately 10/10 high-power fields (HPF; equivalent to 5/mm 2 ), and coagulative tumor necrosis (approximately 15%). Immunohistochemistry demonstrated diffuse strong positivity for CD34 and STAT6, weak positivity for Bcl-2, and focal weak positivity for CDK4 and MDM2. DNA-based next-generation sequencing (NGS) detected an NAB2 :: STAT6 fusion gene and no MDM2 amplification, confirming the diagnosis of myxoid malignant SFT. According to the modified Demicco risk stratification model (age ≥55 years, tumor size 11 cm, mitotic count ≥4/10 HPF, necrosis ≥10%), the case scored 6 points, placing it in the high-risk category. The patient received adjuvant radiotherapy (45 Gy in 25 fractions to the PCTV) and remained disease-free without evidence of recurrence or metastasis throughout the 17-month follow-up period. Malignant myxoid SFT arising in the retroperitoneum is extremely rare and poses significant diagnostic challenges. Accurate diagnosis can be supported by histopathological and immunohistochemical examinations (including CD34, STAT6, and BCL2), and molecular detection of the NAB2 :: STAT6 fusion gene can serve as a valuable adjunct, especially in cases where morphological and immunohistochemical findings are atypical or when differential diagnosis is challenging. Complete surgical resection is the cornerstone of treatment. Adjuvant therapy and close long-term surveillance should be considered for patients with high-risk features. To the best of our knowledge, this case supplements the clinicopathological data of this rare entity occurring in the retroperitoneum with overt malignant biological behavior, and further case reports and studies are essential to refine the diagnostic criteria and optimize treatment strategies for this tumor.
- Open Access
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Angiomatoid fibrous histiocytoma with CDK4 and MDM2 expression misdiagnosed as dedifferentiated liposarcoma: The first case report and literature review
Angiomatoid fibrous histiocytoma is a rare intermediate soft tissue tumor with uncertain differentiation and prone to misdiagnosis because of atypical morphology and aberrant biomarker expression. Herein, we report a unique case of occipital scalp angiomatoid fibrous histiocytoma in a 33-year-old female, which presented with rapid tumor growth, marked nuclear pleomorphism, elevated mitotic activity, and atypical positive expression of CDK4 and MDM2 immunohistochemically, leading to an initial misdiagnosis of dedifferentiated liposarcoma. Preoperative routine blood tests, biochemical examinations, and inflammatory biomarker detection, including C-reactive protein, erythrocyte sedimentation rate, and interleukin-6, were performed, and all hematological indicators were within normal reference ranges without systemic inflammatory or hematological abnormalities. The patient underwent complete marginal resection of the tumor, and no adjuvant radiotherapy or chemotherapy was administered postoperatively because of the absence of high-risk malignant features, residual lesions, and distant metastasis. Molecular testing confirmed EWSR1 gene rearrangement without CDK4 or MDM2 gene amplification, which confirmed the final diagnosis of angiomatoid fibrous histiocytoma. The patient achieved a favorable prognosis with no recurrence or metastasis during 20 months of postoperative follow-up. Distinct from previously reported conventional angiomatoid fibrous histiocytoma cases with low proliferative activity and negative liposarcoma-related markers, the present case is characterized by atypical dual positive expression of CDK4/MDM2 and a markedly elevated Ki-67 proliferation index, which fills the clinical data gap of atypical angiomatoid fibrous histiocytoma with liposarcoma-mimicking immunophenotype. This study further clarifies the differential diagnostic criteria between angiomatoid fibrous histiocytoma and dedifferentiated liposarcoma, verifies that isolated CDK4/MDM2 immunohistochemical positivity cannot independently support the diagnosis of liposarcoma, and highlights the irreplaceable value of molecular testing in the definitive diagnosis of atypical angiomatoid fibrous histiocytoma, providing a reliable reference for pathologists to avoid diagnostic errors in similar rare soft tissue tumors.
- 1 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessAngiomatoid fibrous histiocytoma with CDK4 and MDM2 expression misdiagnosed as dedifferentiated liposarcoma: The first case report and literature review
Angiomatoid fibrous histiocytoma is a rare intermediate soft tissue tumor with uncertain differentiation and prone to misdiagnosis because of atypical morphology and aberrant biomarker expression. Herein, we report a unique case of occipital scalp angiomatoid fibrous histiocytoma in a 33-year-old female, which presented with rapid tumor growth, marked nuclear pleomorphism, elevated mitotic activity, and atypical positive expression of CDK4 and MDM2 immunohistochemically, leading to an initial misdiagnosis of dedifferentiated liposarcoma. Preoperative routine blood tests, biochemical examinations, and inflammatory biomarker detection, including C-reactive protein, erythrocyte sedimentation rate, and interleukin-6, were performed, and all hematological indicators were within normal reference ranges without systemic inflammatory or hematological abnormalities. The patient underwent complete marginal resection of the tumor, and no adjuvant radiotherapy or chemotherapy was administered postoperatively because of the absence of high-risk malignant features, residual lesions, and distant metastasis. Molecular testing confirmed EWSR1 gene rearrangement without CDK4 or MDM2 gene amplification, which confirmed the final diagnosis of angiomatoid fibrous histiocytoma. The patient achieved a favorable prognosis with no recurrence or metastasis during 20 months of postoperative follow-up. Distinct from previously reported conventional angiomatoid fibrous histiocytoma cases with low proliferative activity and negative liposarcoma-related markers, the present case is characterized by atypical dual positive expression of CDK4/MDM2 and a markedly elevated Ki-67 proliferation index, which fills the clinical data gap of atypical angiomatoid fibrous histiocytoma with liposarcoma-mimicking immunophenotype. This study further clarifies the differential diagnostic criteria between angiomatoid fibrous histiocytoma and dedifferentiated liposarcoma, verifies that isolated CDK4/MDM2 immunohistochemical positivity cannot independently support the diagnosis of liposarcoma, and highlights the irreplaceable value of molecular testing in the definitive diagnosis of atypical angiomatoid fibrous histiocytoma, providing a reliable reference for pathologists to avoid diagnostic errors in similar rare soft tissue tumors.
- Open Access
Decoding Roles of Exosomal lncRNAs in Tumor-Immune Regulation and Therapeutic Potential
Exosomes are nanovesicles secreted into biofluids by various cell types and have been implicated in different physiological and pathological processes. Interestingly, a plethora of studies emphasized the mediating role of exosomes in the bidirectional communication between donor and recipient cells. Among the various cargoes of exosomes, long non-coding RNAs (lncRNAs) have been identified as crucial regulators between cancer cells and immune cells in the tumor microenvironment (TME) that can interfere with innate and adaptive immune responses to affect the therapeutic efficiency. Recently, a few major studies have focused on the exosomal lncRNA-mediated interaction between cancer cells and immune cells infiltrated into TME. Nevertheless, a dearth of studies pertains to the immune regulating role of exosomal lncRNAs in cancer and is still in the early stages. Comprehensive mechanisms of exosomal lncRNAs in tumor immunity are not well understood. Herein, we provide an overview of the immunomodulatory function of exosomal lncRNAs in cancer and treatment resistance. In addition, we also summarize the potential therapeutic strategies toward exosomal lncRNAs in TME.
Open AccessDecoding Roles of Exosomal lncRNAs in Tumor-Immune Regulation and Therapeutic Potential
Exosomes are nanovesicles secreted into biofluids by various cell types and have been implicated in different physiological and pathological processes. Interestingly, a plethora of studies emphasized the mediating role of exosomes in the bidirectional communication between donor and recipient cells. Among the various cargoes of exosomes, long non-coding RNAs (lncRNAs) have been identified as crucial regulators between cancer cells and immune cells in the tumor microenvironment (TME) that can interfere with innate and adaptive immune responses to affect the therapeutic efficiency. Recently, a few major studies have focused on the exosomal lncRNA-mediated interaction between cancer cells and immune cells infiltrated into TME. Nevertheless, a dearth of studies pertains to the immune regulating role of exosomal lncRNAs in cancer and is still in the early stages. Comprehensive mechanisms of exosomal lncRNAs in tumor immunity are not well understood. Herein, we provide an overview of the immunomodulatory function of exosomal lncRNAs in cancer and treatment resistance. In addition, we also summarize the potential therapeutic strategies toward exosomal lncRNAs in TME.
- Open Access
- 21 February 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (4) , 1822-1835
Downregulated exosome-associated gene FGF9 as a novel diagnostic and prognostic target for ovarian cancer and its underlying roles in immune regulation
Exosome has been demonstrated to be secreted from cells and seized by targeted cells. Exosome could transmit signals and exert biological functions in cancer progression. Nevertheless, the underlying mechanisms of exosome in ovarian cancer (OC) have not been fully explored. In this study, we wanted to explore whether Fibroblast growth factor 9 (FGF9), as an exosome-associated gene, was importantly essential in OC progression and prognosis. Firstly, comprehensive bioinformatics platforms were applied to find that FGF9 expression was lower in OC tissues compared to normal ovarian tissues. Meanwhile, downregulated FGF9 displayed favorable prognostic values in OC patients. The gene enrichment of biological functions indicated that abnormally expressed FGF9 could be involved in the OC-related immune signatures, such as immunoinhibitors and chemokine receptors. Taken together, these findings could provide a novel insight into the significance of FGF9 in OC progress and supply a new destination of FGF9-related immunotherapy in clinical treatment.
- 21 February 2022
- Published by Impact Journals, LLC in Aging
- Vol. 14 (4) , 1822-1835
Open AccessDownregulated exosome-associated gene FGF9 as a novel diagnostic and prognostic target for ovarian cancer and its underlying roles in immune regulation
Exosome has been demonstrated to be secreted from cells and seized by targeted cells. Exosome could transmit signals and exert biological functions in cancer progression. Nevertheless, the underlying mechanisms of exosome in ovarian cancer (OC) have not been fully explored. In this study, we wanted to explore whether Fibroblast growth factor 9 (FGF9), as an exosome-associated gene, was importantly essential in OC progression and prognosis. Firstly, comprehensive bioinformatics platforms were applied to find that FGF9 expression was lower in OC tissues compared to normal ovarian tissues. Meanwhile, downregulated FGF9 displayed favorable prognostic values in OC patients. The gene enrichment of biological functions indicated that abnormally expressed FGF9 could be involved in the OC-related immune signatures, such as immunoinhibitors and chemokine receptors. Taken together, these findings could provide a novel insight into the significance of FGF9 in OC progress and supply a new destination of FGF9-related immunotherapy in clinical treatment.
- Open Access
- 1 January 2021
- Published by Indian Pharmaceutical Association - IPA in Indian Journal of Pharmaceutical Sciences
- Vol. 83 (s6) , 73-78
Study on Risk Factors of Ventilator-Associated Pneumonia in Elderly Patients with Acute Cerebral Infarction Treated with Endotracheal Intubation and Mechanical Ventilation
To investigate the risk factors of ventilator-associated pneumonia in elderly patients with acute cerebral infarction and to provide guidance for clinical prevention and treatment is the main objective. Gramnegative bacteria 38 strains (67.86 %), Gram-positive bacteria 15 strains (26.79 %) and fungi 3 strains (5.36 %) were detected by pathogenic bacteria culture. There was no significant difference in age, gender, body mass index, smoking, drinking, hypertension, diabetes and coronary heart disease between ventilator-associated pneumonia group and non-ventilator-associated pneumonia group (p>0.05); there were significant differences between ventilator-associated pneumonia group and non-ventilator-associated pneumonia group in antibiotic prophylactic use, time of ventilator use, acute physiology and chronic health evaluation II score and serum albumin level (p<0.05). The receiver operating characteristic curve was drawn and the results showed that the sensitivity of acute physiology and chronic health evaluation II score in predicting ventilator-associated pneumonia in patients with acute cerebral infarction was 93.71 %, the specificity was 77.61 % and the area under the curve value was 0.894. The sensitivity and specificity of albumin in predicting ventilator-associated pneumonia in elderly patients with acute cerebral infarction were 78.51 %, 76.92 % and 0.857 respectively. Multivariate logistic analysis showed that prophylactic use of antibiotics and high serum albumin level could effectively reduce the risk of ventilator-associated pneumonia in elderly patients with acute cerebral infarction undergoing endotracheal intubation and mechanical ventilation (p<0.05), while prolonged time of ventilator use and increased acute physiology and chronic health evaluation II score would increase the risk of ventilator-associated pneumonia in elderly patients with undergoing endotracheal intubation and mechanical ventilation (p<0.05). There are many factors influencing the occurrence of ventilator-associated pneumonia in the elderly patients with acute cerebral infarction undergoing endotracheal intubation and mechanical ventilation, and the intervention according to the risk factors has a positive preventive effect.
- 1 January 2021
- Published by Indian Pharmaceutical Association - IPA in Indian Journal of Pharmaceutical Sciences
- Vol. 83 (s6) , 73-78
Open AccessStudy on Risk Factors of Ventilator-Associated Pneumonia in Elderly Patients with Acute Cerebral Infarction Treated with Endotracheal Intubation and Mechanical Ventilation
To investigate the risk factors of ventilator-associated pneumonia in elderly patients with acute cerebral infarction and to provide guidance for clinical prevention and treatment is the main objective. Gramnegative bacteria 38 strains (67.86 %), Gram-positive bacteria 15 strains (26.79 %) and fungi 3 strains (5.36 %) were detected by pathogenic bacteria culture. There was no significant difference in age, gender, body mass index, smoking, drinking, hypertension, diabetes and coronary heart disease between ventilator-associated pneumonia group and non-ventilator-associated pneumonia group (p>0.05); there were significant differences between ventilator-associated pneumonia group and non-ventilator-associated pneumonia group in antibiotic prophylactic use, time of ventilator use, acute physiology and chronic health evaluation II score and serum albumin level (p<0.05). The receiver operating characteristic curve was drawn and the results showed that the sensitivity of acute physiology and chronic health evaluation II score in predicting ventilator-associated pneumonia in patients with acute cerebral infarction was 93.71 %, the specificity was 77.61 % and the area under the curve value was 0.894. The sensitivity and specificity of albumin in predicting ventilator-associated pneumonia in elderly patients with acute cerebral infarction were 78.51 %, 76.92 % and 0.857 respectively. Multivariate logistic analysis showed that prophylactic use of antibiotics and high serum albumin level could effectively reduce the risk of ventilator-associated pneumonia in elderly patients with acute cerebral infarction undergoing endotracheal intubation and mechanical ventilation (p<0.05), while prolonged time of ventilator use and increased acute physiology and chronic health evaluation II score would increase the risk of ventilator-associated pneumonia in elderly patients with undergoing endotracheal intubation and mechanical ventilation (p<0.05). There are many factors influencing the occurrence of ventilator-associated pneumonia in the elderly patients with acute cerebral infarction undergoing endotracheal intubation and mechanical ventilation, and the intervention according to the risk factors has a positive preventive effect.
- 31 August 2019
- Published by Wiley in Immunology & Cell Biology
- Vol. 97 (10) , 902-915
LDK378 inhibits the recruitment of myeloid‐derived suppressor cells to spleen via the p38–GRK2–CCR2 pathway in mice with sepsis
Myeloid‐derived suppressor cells (MDSCs) are functionally immunosuppressive cells that are persistently increased in abundance and associated with adverse clinical outcomes in sepsis. Here, we investigated the therapeutic potential of an anaplastic lymphoma kinase inhibitor, LDK378, in cecal ligation and puncture (CLP)‐induced polymicrobial sepsis and examined its effects on the recruitment of MDSCs. LDK378 significantly improved the survival of CLP‐induced polymicrobial septic mice, which was paralleled by reduced organ injury, decreased release of inflammatory cytokines and decreased recruitment of MDSCs to the spleen. Importantly, LDK378 inhibited the migration of MDSCs to the spleen by blocking the CLP‐mediated upregulation of CC chemokine receptor 2 (CCR2), a chemokine receptor critical for the recruitment of MDSCs. Mechanistically, LDK378 treatment blocked the CLP‐induced CCR2 upregulation of MDSCs via partially inhibiting the phosphorylation of p38 and G‐protein‐coupled receptor kinase‐2 (GRK2) in bone marrow MDSCs of septic mice. Furthermore, in vitro experiments also showed that lipopolysaccharide (LPS)‐induced migration of MDSCs was similarly owing to the activation of GRK2 and upregulation of CCR2 by LPS, whereas the treatment with LDK378 partially blocked the LPS‐induced phosphorylation of p38 and GRK2 and decreased the expression of CCR2 on the cell surface, therefore leading to the suppression of MDSC migration. Together, these findings unravel a novel function of LDK378 in the host response to infection and suggest that LDK378 could be a potential therapeutic agent for sepsis.See also: News and Commentary by Patil
- 31 August 2019
- Published by Wiley in Immunology & Cell Biology
- Vol. 97 (10) , 902-915
LDK378 inhibits the recruitment of myeloid‐derived suppressor cells to spleen via the p38–GRK2–CCR2 pathway in mice with sepsis
Myeloid‐derived suppressor cells (MDSCs) are functionally immunosuppressive cells that are persistently increased in abundance and associated with adverse clinical outcomes in sepsis. Here, we investigated the therapeutic potential of an anaplastic lymphoma kinase inhibitor, LDK378, in cecal ligation and puncture (CLP)‐induced polymicrobial sepsis and examined its effects on the recruitment of MDSCs. LDK378 significantly improved the survival of CLP‐induced polymicrobial septic mice, which was paralleled by reduced organ injury, decreased release of inflammatory cytokines and decreased recruitment of MDSCs to the spleen. Importantly, LDK378 inhibited the migration of MDSCs to the spleen by blocking the CLP‐mediated upregulation of CC chemokine receptor 2 (CCR2), a chemokine receptor critical for the recruitment of MDSCs. Mechanistically, LDK378 treatment blocked the CLP‐induced CCR2 upregulation of MDSCs via partially inhibiting the phosphorylation of p38 and G‐protein‐coupled receptor kinase‐2 (GRK2) in bone marrow MDSCs of septic mice. Furthermore, in vitro experiments also showed that lipopolysaccharide (LPS)‐induced migration of MDSCs was similarly owing to the activation of GRK2 and upregulation of CCR2 by LPS, whereas the treatment with LDK378 partially blocked the LPS‐induced phosphorylation of p38 and GRK2 and decreased the expression of CCR2 on the cell surface, therefore leading to the suppression of MDSC migration. Together, these findings unravel a novel function of LDK378 in the host response to infection and suggest that LDK378 could be a potential therapeutic agent for sepsis.See also: News and Commentary by Patil